Trials / Available
AvailableNCT05494411
Named Patient Program for Mitomycin for Pyelocalyceal Solution
- Status
- Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- UroGen Pharma Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
This program provides controlled, pre-approval access to JELMYTO in response to unsolicited requests by physicians, hospitals, pharmacies, distributors, ministries of health or other parties on behalf of specific, or named patients, in select countries where JELMYTO has not yet received a marketing authorization and in situations when patients have exhausted all available treatment options.
Conditions
- Urothelial Cancer of Renal Pelvis
- Urothelial Carcinoma of the Renal Pelvis and Ureter
- Urothelial Carcinoma Ureter
- Urothelial Carcinoma Ureter Recurrent
- Urothelial Carcinoma
- Urothelial Carcinoma Recurrent
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mitomycin for pyelocalyceal solution |
Timeline
- First posted
- 2022-08-10
- Last updated
- 2025-02-28
Source: ClinicalTrials.gov record NCT05494411. Inclusion in this directory is not an endorsement.